Circulating Cell-Free DNA Is a Non-Invasive Marker of Heart Transplant Rejection

2014 ◽  
Vol 33 (4) ◽  
pp. S84-S85 ◽  
Author(s):  
I. De Vlaminck ◽  
H.A. Valantine ◽  
H. Luikart ◽  
D. Weisshaar ◽  
D. Bernstein ◽  
...  
2014 ◽  
Vol 6 (241) ◽  
pp. 241ra77-241ra77 ◽  
Author(s):  
I. De Vlaminck ◽  
H. A. Valantine ◽  
T. M. Snyder ◽  
C. Strehl ◽  
G. Cohen ◽  
...  

2018 ◽  
Vol 37 (4) ◽  
pp. S78-S79 ◽  
Author(s):  
H. Valantine ◽  
P. Shah ◽  
K. Shah ◽  
S. Hsu ◽  
E. Feller ◽  
...  

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Brian C.-H. Chiu ◽  
Chang Chen ◽  
Qiancheng You ◽  
Rudyard Chiu ◽  
Girish Venkataraman ◽  
...  

AbstractThe 5-methylcytosines (5mC) have been implicated in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). However, the role of 5-hydroxymethylcytosines (5hmC) that are generated from 5mC through active demethylation, in lymphomagenesis is unknown. We profiled genome-wide 5hmC in circulating cell-free DNA (cfDNA) from 73 newly diagnosed patients with DLBCL and FL. We identified 294 differentially modified genes between DLBCL and FL. The differential 5hmC in the DLBCL/FL-differentiating genes co-localized with enhancer marks H3K4me1 and H3K27ac. A four-gene panel (CNN2, HMG20B, ACRBP, IZUMO1) robustly represented the overall 5hmC modification pattern that distinguished FL from DLBCL with an area under curve of 88.5% in the testing set. The median 5hmC modification levels in signature genes showed potential for separating patients for risk of all-cause mortality. This study provides evidence that genome-wide 5hmC profiles in cfDNA differ between DLBCL and FL and could be exploited as a non-invasive approach.


2018 ◽  
Vol 20 ◽  
Author(s):  
Ana Barbosa ◽  
Ana Peixoto ◽  
Pedro Pinto ◽  
Manuela Pinheiro ◽  
Manuel R. Teixeira

AbstractCirculating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called ‘liquid biopsy’, as a non-invasive cancer biomarker has recently received a lot of attention. The present review will focus on studies concerning the potential clinical applications of cfDNA in ovarian cancer patients.


Sign in / Sign up

Export Citation Format

Share Document